BACKGROUND & AIMS: Celiac disease is a polygenic disorder associated with HLA-DQ2 or HLA-DQ8, which are present in greater than 90% of patients. The disease is considered milder in the United States compared with Europe. We assessed whether differences in the frequency of HLA type may account for differences in severity of the disease by using cohorts of patients from New York and Paris. METHODS: HLA-DQ typing was performed on patients with celiac disease in New York and Paris. Clinical and pathologic data were compared between the New York and Parisian cohorts and also correlated with the different HLA types (HLA-DQ2, HLA-DQ2/-DQ8, HLA-DQ8). RESULTS: Among these patients, the disease was milder in the New York cohort compared with the Parisian cohort. There were fewer patients with a classical presentation (45% and 89%, respectively; P < 0.001) and less severe pathology (total villous atrophy, 64% and 89%, respectively; P < 0.05), and less marked intraepithelial lymphocytosis (intraepithelial leukocytes [IELs]/100 enterocytes, 48.1 and 82.5, respectively; P < 0.0001). HLA-DQ2 homozygotes were less prevalent in the New York cohort compared with the Parisian cohort (59% and 79%, respectively; P = 0.08). HLA-DQ8 alleles were more prevalent in the New York cohort compared with the Parisian cohort (41% and 21%, respectively; P = 0.026). There was, however, no difference in the clinical or pathologic parameters of severity when we compared the groups based on HLA type. CONCLUSIONS: HLA-DQ8 alleles were increased in the New York cohort of patients with celiac disease; however, this did not account for less severe manifestations of the disease.
BACKGROUND & AIMS:Celiac disease is a polygenic disorder associated with HLA-DQ2 or HLA-DQ8, which are present in greater than 90% of patients. The disease is considered milder in the United States compared with Europe. We assessed whether differences in the frequency of HLA type may account for differences in severity of the disease by using cohorts of patients from New York and Paris. METHODS: HLA-DQ typing was performed on patients with celiac disease in New York and Paris. Clinical and pathologic data were compared between the New York and Parisian cohorts and also correlated with the different HLA types (HLA-DQ2, HLA-DQ2/-DQ8, HLA-DQ8). RESULTS: Among these patients, the disease was milder in the New York cohort compared with the Parisian cohort. There were fewer patients with a classical presentation (45% and 89%, respectively; P < 0.001) and less severe pathology (total villous atrophy, 64% and 89%, respectively; P < 0.05), and less marked intraepithelial lymphocytosis (intraepithelial leukocytes [IELs]/100 enterocytes, 48.1 and 82.5, respectively; P < 0.0001). HLA-DQ2 homozygotes were less prevalent in the New York cohort compared with the Parisian cohort (59% and 79%, respectively; P = 0.08). HLA-DQ8 alleles were more prevalent in the New York cohort compared with the Parisian cohort (41% and 21%, respectively; P = 0.026). There was, however, no difference in the clinical or pathologic parameters of severity when we compared the groups based on HLA type. CONCLUSIONS: HLA-DQ8 alleles were increased in the New York cohort of patients with celiac disease; however, this did not account for less severe manifestations of the disease.
Authors: Reem Z Sharaiha; Ben Lebwohl; Laura Reimers; Govind Bhagat; Peter H Green; Alfred I Neugut Journal: Cancer Date: 2011-12-13 Impact factor: 6.860
Authors: Anna Licata; Maria Cappello; Andrea Arini; Ada M Florena; Claudia Randazzo; Giuseppe Butera; Piero L Almasio; Antonio Craxì Journal: Intern Emerg Med Date: 2011-04-06 Impact factor: 3.397
Authors: Tieying Hou; Henriette Macmillan; Zhenjun Chen; Catherine L Keech; Xi Jin; John Sidney; Michael Strohman; Taejin Yoon; Elizabeth D Mellins Journal: J Immunol Date: 2011-07-20 Impact factor: 5.422
Authors: Joseph A Murray; S Breanndan Moore; Carol T Van Dyke; Brian D Lahr; Ross A Dierkhising; Alan R Zinsmeister; L Joseph Melton; Cynthia M Kroning; Mounif El-Yousseff; Albert J Czaja Journal: Clin Gastroenterol Hepatol Date: 2007-10-24 Impact factor: 11.382
Authors: Robert Busch; Alessandra De Riva; Andreas V Hadjinicolaou; Wei Jiang; Tieying Hou; Elizabeth D Mellins Journal: Expert Rev Mol Med Date: 2012-07-06 Impact factor: 5.600
Authors: Margarida Maria Castro-Antunes; Sergio Crovella; Lucas Andre Cavalcanti Brandão; Rafael Lima Guimaraes; Maria Eugênia Farias Almeida Motta; Giselia Alves Pontes da Silva Journal: Clinics (Sao Paulo) Date: 2011 Impact factor: 2.365